Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Pursues Internal Development While Seeking External Opportunities

Executive Summary

Novartis is using a combination of its own internal development, in-licensing deal and acquisitions to bolster its pipeline. Novartis Head of Pharma Development James Shannon recently spoke with "The Pink Sheet" DAILY to discuss the company's development priorities.

You may also be interested in...



Novartis’ New Vaccine Division Takes On Evolving Market

Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said

Novartis’ New Vaccine Division Takes On Evolving Market

Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said

Novartis Proposes Two-Phase Drug Development Model, Staged Approval

Novartis is advocating a two-phase drug development paradigm based on "models of disease.

UsernamePublicRestriction

Register

PS047436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel